Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2060-2069

  Kumar, Pawan ^a   Gao, Qinghong ^a,b   Ning, Yu ^a   Wang, Zhuo ^a   Krebsbach, Paul H ^a   Polverini, Peter J ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUDITORY OSSICLE; BONE DESTRUCTION; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; MOUSE; MOUTH CARCINOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; RADIATION DOSE; SEVERE COMBINED IMMUNODEFICIENCY; SKIN CELL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BONE; DOSE RESPONSE; DRUG SCREENING; IONIZING RADIATION; METASTASIS; MOUSE MUTANT; MOUTH TUMOR; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ARSENICALS; BONE AND BONES; BONE RESORPTION; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; OXIDES; RADIATION, IONIZING; TREATMENT OUTCOME; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51049120761     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0287     Document Type: Article

References (34)

1. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005;24:9-17.
2. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology 1975;114:155-62.
3. Green N, French S, Rodriquez G, Hays M, Fingerhut A. Radiation-induced delayed union of fractures. Radiology 1969;93:635-41.
4. Gal TJ, Munoz-Antonia T, Muro-Cacho CA, Klotch DW. Radiation effects on osteoblasts in vitro: a potential role in osteoradionecrosis. Arch Otolaryngol Head Neck Surg 2000;126:1124-8.
5. Howland WJ, Loeffler RK, Starchman DE, Johnson RG. Postirradiation atrophic changes of bone and related complications. Radiology 1975;117:677-85.
6. Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev 2002;28:65-74.
7. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
8. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
9. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6 Suppl 2:22-8.
10. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6 Suppl 2:3-10.
11. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525-30.
12. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood 1996;88:1052-61.
13. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-33.
14. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-8.
15. Kumar P, Miller AI, Polverini PJ. p38 MAPK mediates γ-irradiation- induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 2004;279:43352-60.
16. Wu J, Haugk K, Plymate SR. Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGFIR. Horm Metab Res 2003;35:751-7.
17. Lowe LC, Senaratne SG, Colston KW. Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem Biophys Res Commun 2005;329:772-9.
18. Juretic N, Santibanez JF, Hurtado C, Martinez J. ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J Cell Biochem 2001;83:92-8.
19. Noth U, Tuli R, Seghatoleslami R, et al. Activation of p38 and Smads mediates BMP-2 effects on human trabecular bone-derived osteoblasts. Exp Cell Res 2003;291:201-11.
20. Shim MJ, Kim HJ, Yang SJ, et al. Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol 2002;35:377-83.
21. Verma A, Mohindru M, Deb DK, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277:44988-95.
22. Kumar P, Benedict R, Urzua F, et al. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 2005;85:756-67.
23. Schneider A, Taboas JM, McCauley LK, Krebsbach PH. Skeletal homeostasis in tissue-engineered bone. J Orthop Res 2003;21:859-64.
24. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000;78:476-86.
25. Krebsbach PH, Kuznetsov SA, Satomura K, et al. Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation 1997;63:1059-69.
26. Kao YH, Yu CL, Chang LW, Yu HS. Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem Res Toxicol 2003;16:460-8.
27. Soucy NV, Ihnat MA, Kamat CD, et al. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci 2003;76:271-9.
28. Barchowsky A, Roussel RR, Klei LR, et al. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 1999;159:65-75.
29. Simeonova PP, Wang S, Hulderman T, Luster MI. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 2002;277:2945-50.
30. Agis H, Weltermann A, Mitterbauer G, et al. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol 1999;78:329-32.
31. Kumar P, Coltas IK, Kumar B, et al. Bcl-2 protects endothelial cells against γ-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. Cancer Res 2007;67:1193-202.
32. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851-60.
33. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-7.
34. Griffin RJ, Williams BW, Park HJ, Song CW. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys 2005;61:1516-22.